China Quantitative Biomedicine

China Quantitative Biomedicine (CQB) is a contract manufacturing organization (CMO) specializing in cGMP biologics production, located in the China Medical City (CMC) in Taizhou, Jiangsu Province. Established in 2008 through a merger of Pacific Biopharma Group and PacificGMP, the company operates a state-of-the-art 200,000-square-foot facility designed to meet FDA and EMEA standards. CQB utilizes advanced single-use biomanufacturing technology to produce proteins and other biologics for global markets, including the US, Europe, and Asia. The company has historically served as a critical bridge for translational development between the US and China, supporting projects from the California Institute for Quantitative Biosciences (QB3). It provides manufacturing services for late-stage clinical supplies and commercial biopharmaceutical products.